Biopharmaceutical Company, Amcure insisted on extending its team of members by further appointing Heinz Dieter Schwer, PhD, MBA, CEO of ViraTherapeutics.
Klaus Dembowsky, MD, PhD, CEO of amcure stated “To attract Heinz is a great achievement for amcure and we look forward to his contributions as we move our lead candidate, AMC303 through the clinic in 2018, to treat patients with advanced solid tumors of epithelial origins.”
Heinz Schwer, PhD, MBA, is currently the CEO of ViraTherapeutics, an Austrian-based biotechnology company developing immunotherapeutics for cancer treatment. Prior to joining ViraTherapeutics, Dr. Schwer served as CEO of therapeutic peptide developer, Lanthio Pharma B.V. from 2014-2017. Before his time at Lanthio, Dr. Schwer was Senior Director at MorphoSys AG from 2010 until 2014. In this period, he served as strategic technology advisor and head of “Innovation Capital”, the company’s corporate venture business. He was previously founder and CEO of Sloning BioTechnology GmbH, which was acquired by MorphoSys, where he managed the integration of the Slonomics technology platform. Dr. Schwer did his postdoctoral fellowship training at Harvard Medical School, USA after having completed his PhD in clinical chemistry from the University of Regensburg, Germany. He also holds an MBA degree from Henley Management College, UK.